Kara A. McRae, PhD


Sr. Epidemiologist
Variable Solutions, LLC
Richmond, Virginia, USA

Biography

Dr. McRae is a private research consultant. Her expertise is in health system, policy, and public health program evaluation. She recently joined the Virginia Department of Public Health as the Epidemiologist for the COVID-19 outbreak response in rural central Virginia. Her current focus is rural public health and health policy.

Education

• (2017) PhD, Health Services Research. Colorado School of Public Health
• (2003) MSPH, Epidemiology. University of Colorado Health Sciences Center
• (1991) BA, University of North Texas

Research Interest

Her research interest includes: Rural public health and health policy.

Scientific Activities

Publications

1. McRae KA. The Effect of Medical Home Legislation on Colorado’s Pediatric Practices and Health Services use in Children on Medicaid. [dissertation]. Ann Arbor, MI, USA: University of Colorado Denver, Anschutz Medical Campus; 2017.
2. McRae KA. HIV Sero sruveillance in Men Who have Sex with Men in Colorado. 1998-2002. [Thesis]. 2004.
3. Picklar. Improving medical homes and transition outcomes for youth served in IMD clinics, The NCC Collaborator. 2010; 4(1).
4. Vu. Public versus private health insurance in colorado at a glance: A glimpse at health care coverage, health behaviors and chronic conditions using the BRFSS. Colorado Department of Public Health and Environment, Health Watch. 2010.
5. McRae KA. Maternal indicators for women on medicaid in colorado: An analysis of pregnancy risk assessment monitoring system (PRAMS) survey data. Colorado Department of Public Health and Environment. Health Watch. 2009.
6. McRae KA. Progress of Colorado’s health care program for children and youth with special health care needs progress in meeting maternal and child health (MCH) outcome measures for 2002-2004. Research findings were presented CAHPS User Network Webcast. Denver, CO. 2005.
7. Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry. 2005; 162(2): 386-388. doi: 10.1176/appi.ajp.162.2.386
8. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004; 161(10): 1822-1828. doi: 10.1176/ajp.161.10.1822
9. Olincy A, Ross RG, Harris JG, Young DA, McAndrews MA, Cawthra E, et al. The P50 auditory event-evoked potential in adult attention-deficit disorder: Comparison with schizophrenia. Biol Psychiatry. 2000; 47(11): 969-977. doi: 10.1016/s0006-3223(00)00239-0
10. Arciniegas D, Olincy A, Topkoff J, McRae K, Cawthra E, Filley CM, et al. Impaired auditory gating and P50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2000; 12(1): 77-85. doi: 10.1176/jnp.12.1.77
11. Nagamoto HT, Adler LE, McRae KA, Huettl P, Cawthra E, Gerhardt G, et al. Auditory P50 in schizophrenics on clozapine: Improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology. 1999; 39(1): 10-17. doi: 10.1159/000026553
12. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R, et al. Gating of auditory P50 in schizophrenics: Unique effects of clozapine. Biol Psychiatry. 1996; 40(3): 181-188. doi: 10.1016/0006-3223(95)00371-1
13. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, et al. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch Gen Psychiatry. 1996; 53(12): 1114-1121. doi: 10.1001/archpsyc.1996.01830120052009